RxDoctor Payments Data

Elizabeth Vickers, APRN

Family · Lexington, KYNPI 1760979041

Payments from drug & device makers

$7,984in general payments, 2019–2025

Across 208 payments — averaging $38.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$3K
  • Medtronic$2K
  • Sumitomo Pharma America, Inc.$393
  • Astellas Pharma US Inc$372
  • Axonics, Inc.$329
  • Ferring Pharmaceuticals Inc.$310
  • plus $2K from 26 others

What the payments were for

  • Travel & lodging$1,58220%
  • Food & beverage$6,11677%
  • Education$2864%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,984 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$96,085
Medicare patients
445
Services billed
12,009

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron359$275,052
GemtesaVibegron169$152,847
Mirabegron ErMirabegron43$33,176
Estradiol118$7,125
Methenamine Hippurate117$6,148
Fesoterodine Fumarate ErFesoterodine Fumarate83$4,982
Solifenacin Succinate194$4,429
Tamsulosin Hcl357$4,041
Oxybutynin Chloride ErOxybutynin Chloride146$3,447
Bethanechol Chloride68$3,194
Tolterodine Tartrate ErTolterodine Tartrate17$2,636
Finasteride111$1,622
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst133$1,576
Silodosin27$1,201
Trimethoprim30$986

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$372$275,052359 claims
Sumitomo Pharma America, Inc.Gemtesa$393$152,847169 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.

Other family in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →